Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piccart

Showing results (111-120 of 186) with videos related to

Pageof 19
Sort By:
International Journal of Oncology|October 20, 2004
Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancerV Durbecq, C Desmed, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials GroupW W ten Bokkel Huinink, A M Prove, M Piccart, et al.
British Journal of Cancer|May 5, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursA Awada, A Hendlisz, T Gil, et al.
Clinical Breast Cancer|April 24, 2002
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen controlR Paridaens, L Dirix, L Beex, et al.
Breast Cancer Research and Treatment|June 9, 2000
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancerA Hamilton, J A Roy, L Beex, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complexP F Dodion, D de Valeriola, N Crespeigne, et al.
ESMO Open|April 25, 2025
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balanceS Lobo-Martins, L Arecco, T P Cabral, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerR Paridaens, L Dirix, C Lohrisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2013
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialC Criscitiello, H A Azim, D Agbor-tarh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'G Atalay, L Dirix, L Biganzoli, et al.
Pageof 19

Showing results (111-120 of 186) with videos related to

Sort By:
Pageof 19
International Journal of Oncology|October 20, 2004
Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancerV Durbecq, C Desmed, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials GroupW W ten Bokkel Huinink, A M Prove, M Piccart, et al.
British Journal of Cancer|May 5, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursA Awada, A Hendlisz, T Gil, et al.
Clinical Breast Cancer|April 24, 2002
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen controlR Paridaens, L Dirix, L Beex, et al.
Breast Cancer Research and Treatment|June 9, 2000
EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancerA Hamilton, J A Roy, L Beex, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complexP F Dodion, D de Valeriola, N Crespeigne, et al.
ESMO Open|April 25, 2025
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balanceS Lobo-Martins, L Arecco, T P Cabral, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerR Paridaens, L Dirix, C Lohrisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2013
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialC Criscitiello, H A Azim, D Agbor-tarh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'G Atalay, L Dirix, L Biganzoli, et al.
Pageof 19